Exclusive deal on hepatitis C drugs signed between Gilead Sciences and CVS

January 6, 2015 12:13 PM

9 0

Exclusive deal on hepatitis C drugs signed between Gilead Sciences and CVS

In a move that intensifies a drug-industry rivalry to win patients for the $1,000-a-day medicines, Gilead Sciences Inc. has agreed to make its hepatitis C medicines the exclusive treatments for CVS Health Corp. customers.

The main list of drugs by CVS will have Gilead's Harvoni and Sovaldi. The same goes for its list for health plans through the Affordable Care Act, Medicare Part D and Medicaid. The information about the same has been provided by the benefits manager on Monday.

Also read: Coke CEO Muhtar Kent to step down May 1

Read more

To category page

Loading...